161 related articles for article (PubMed ID: 31692952)
21. Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma.
Jou YC; Tsai YS; Hsieh HY; Chen SY; Tsai HT; Chen KJ; Wang ST; Shiau AL; Wu CL; Tzai TS
Urol Oncol; 2013 Nov; 31(8):1806-11. PubMed ID: 22609059
[TBL] [Abstract][Full Text] [Related]
22. Elevated levels of serum aldolase A in patients with renal cell carcinoma.
Takashi M; Zhu Y; Nakano Y; Miyake K; Kato K
Urol Res; 1992; 20(4):307-11. PubMed ID: 1509638
[TBL] [Abstract][Full Text] [Related]
23. iTRAQ-Based Quantitative Proteomic Analysis Identified HSC71 as a Novel Serum Biomarker for Renal Cell Carcinoma.
Zhang Y; Cai Y; Yu H; Li H
Biomed Res Int; 2015; 2015():802153. PubMed ID: 26425554
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor.
Tanimoto S; Fukumori T; El-Moula G; Shiirevnyamba A; Kinouchi S; Koizumi T; Nakanishi R; Yamamoto Y; Taue R; Yamaguchi K; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Takahashi M; Kanayama HO
J Med Invest; 2008 Feb; 55(1-2):106-11. PubMed ID: 18319552
[TBL] [Abstract][Full Text] [Related]
25. [Prognostic value of serum immunosuppressive acidic protein in renal cell carcinoma].
Matsumoto K; Iwamura M; Muramoto M; Suyama K; Tabata K; Minei S; Hirai S; Baba S
Nihon Hinyokika Gakkai Zasshi; 2002 May; 93(4):548-54. PubMed ID: 12056039
[TBL] [Abstract][Full Text] [Related]
26. [Proteomic analysis in combination with CT diagnosis to distinguish renal cell carcinoma from renal benign masses].
Xu G; Xiang CQ; Lu Y; Kang XN; Wang WJ; Liao P; Ding Q; Zhang YF
Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(12):858-60. PubMed ID: 18756995
[TBL] [Abstract][Full Text] [Related]
27. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
Xu G; Xiang CQ; Lu Y; Kang XN; Liao P; Ding Q; Zhang YF
Cancer Lett; 2009 Sep; 282(2):205-13. PubMed ID: 19362769
[TBL] [Abstract][Full Text] [Related]
28. Preoperative high levels of serum vascular endothelial growth factor are a prognostic marker for poor outcome after surgical treatment of renal cell carcinoma.
Guðbrandsdottir G; Hjelle KM; Frugård J; Bostad L; Aarstad HJ; Beisland C
Scand J Urol; 2015; 49(5):388-94. PubMed ID: 25773545
[TBL] [Abstract][Full Text] [Related]
29. Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma.
Fedorko M; Stanik M; Iliev R; Redova-Lojova M; Machackova T; Svoboda M; Pacik D; Dolezel J; Slaby O
Int J Mol Sci; 2015 Sep; 16(10):23382-9. PubMed ID: 26426010
[TBL] [Abstract][Full Text] [Related]
30. Circulating adiponectin as a biomarker in renal cell carcinoma: a systematic review and meta-analysis.
Yap NY; Yap FN; Perumal K; Rajandram R
Biomarkers; 2019 Sep; 24(6):607-614. PubMed ID: 31215811
[No Abstract] [Full Text] [Related]
31. Urinary NMP22 and renal cell carcinoma.
Huang S; Rhee E; Patel H; Park E; Kaswick J
Urology; 2000 Feb; 55(2):227-30. PubMed ID: 10688084
[TBL] [Abstract][Full Text] [Related]
32. Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma.
Nakanishi S; Goya M; Suda T; Yonamine T; Sugawa A; Saito S
BMC Urol; 2024 Apr; 24(1):94. PubMed ID: 38658967
[TBL] [Abstract][Full Text] [Related]
33. The Diagnostic Value of FNDC5/Irisin in Renal Cell Cancer.
Altay DU; Keha EE; Karagüzel E; Menteşe A; Yaman SO; Alver A
Int Braz J Urol; 2018; 44(4):734-739. PubMed ID: 29522296
[TBL] [Abstract][Full Text] [Related]
34. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma.
Sato K; Tsuchiya N; Sasaki R; Shimoda N; Satoh S; Ogawa O; Kato T
Jpn J Cancer Res; 1999 Aug; 90(8):874-9. PubMed ID: 10543260
[TBL] [Abstract][Full Text] [Related]
35. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
36. Tumour-associated trypsin inhibitor and renal cell carcinoma.
Meria P; Toubert ME; Cussenot O; Bassi S; Janssen T; Desgrandchamps F; Cortesse A; Schlageter MH; Teillac P; Le Duc A
Eur Urol; 1995; 27(3):223-6. PubMed ID: 7601186
[TBL] [Abstract][Full Text] [Related]
37. An In-vivo Prospective Study of the Diagnostic Yield and Accuracy of Optical Biopsy Compared with Conventional Renal Mass Biopsy for the Diagnosis of Renal Cell Carcinoma: The Interim Analysis.
Buijs M; Wagstaff PGK; de Bruin DM; Zondervan PJ; Savci-Heijink CD; van Delden OM; van Leeuwen TG; van Moorselaar RJA; de la Rosette JJMCH; Laguna Pes MP
Eur Urol Focus; 2018 Dec; 4(6):978-985. PubMed ID: 29079496
[TBL] [Abstract][Full Text] [Related]
38. Serum M65 as a biomarker for metastatic renal cell carcinoma.
Yildiz I; Sen F; Kilic L; Keskin S; Duranyildiz D; Bilgin E; Disci R; Ekenel M; Darendeliler E; Bavbek S; Basaran M
Clin Genitourin Cancer; 2013 Sep; 11(3):290-6. PubMed ID: 23391372
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of preoperative kidney volume for predicting renal function in renal cell carcinoma patients receiving a radical or partial nephrectomy.
Jeon HG; Gong IH; Hwang JH; Choi DK; Lee SR; Park DS
BJU Int; 2012 May; 109(10):1468-73. PubMed ID: 21883863
[TBL] [Abstract][Full Text] [Related]
40. Serum-soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage.
Thompson RH; Zang X; Lohse CM; Leibovich BC; Slovin SF; Reuter VE; Cheville JC; Blute ML; Russo P; Kwon ED; Allison JP
Cancer Res; 2008 Aug; 68(15):6054-8. PubMed ID: 18676826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
